Survey for Retinopathy Screening Devices Market
Physicians and Hospital Administrators
100 Physicians, including 50 Group Practice Primary Care Physicians (PCPs), 25 Individual Practice PCPs and 25 Endocrinologists; 25 Hospital Administrators
Several different strategies to promote widespread screening for diabetic retinopathy are being implemented across the United States and around the world. In the U.S., the success of these strategies will depend on the extent to which they are able to provide much needed services in a way that is sustainable under evolving economic and legislative conditions. Successful strategies for bringing solutions to market will be informed by the preferences of physicians and other health care providers in the context of legislative incentives, economic constraints and the demands of a changing patient population.
This report, based on a combined market and end-user study, is designed to act as a guidebook for companies and policy makers attempting to navigate this complex economic and political landscape. The study addresses the following questions:
1. Are physicians and hospital administrators ready to take concrete steps toward managing widespread diabetes and diabetic retinopathy?
2. What financial and other motivations drive these groups to make purchasing decisions?
3. What pricing thresholds would be acceptable to different groups of purchasers?
4. What logistical issues have the potential to accelerate or stall implementation of new solutions?
100 Physicians, including 50 Group Practice Primary Care Physicians (PCPs), 25 Individual Practice PCPs and 25 Endocrinologists; 25 Hospital Administrators
Several different strategies to promote widespread screening for diabetic retinopathy are being implemented across the United States and around the world. In the U.S., the success of these strategies will depend on the extent to which they are able to provide much needed services in a way that is sustainable under evolving economic and legislative conditions. Successful strategies for bringing solutions to market will be informed by the preferences of physicians and other health care providers in the context of legislative incentives, economic constraints and the demands of a changing patient population.
This report, based on a combined market and end-user study, is designed to act as a guidebook for companies and policy makers attempting to navigate this complex economic and political landscape. The study addresses the following questions:
1. Are physicians and hospital administrators ready to take concrete steps toward managing widespread diabetes and diabetic retinopathy?
2. What financial and other motivations drive these groups to make purchasing decisions?
3. What pricing thresholds would be acceptable to different groups of purchasers?
4. What logistical issues have the potential to accelerate or stall implementation of new solutions?
EXECUTIVE SUMMARY
1.1 SCOPE OF STUDY
1.2 MARKET ANALYSIS AND FORECASTS
1.3 PHYSICIAN AND HOSPITAL ADMINISTRATOR SURVEY
RESEARCH METHODOLOGY
2.1 RESEARCH SCOPE
2.2 IDATA’S 9- Step METHODOLOGY
2.2.1 Step 1: Project Initiation & Team Selection
2.2.2 Step 2: Prepare Data Systems and Perform Secondary Research
2.2.3 Step 3: Preparation for Interviews & Questionnaire Design
2.2.4 Step 4: Performing Primary Research
2.2.5 Step 5: Research Analysis: Establishing Baseline Estimates
2.2.6 Step 6: Market Forecast and Analysis
2.2.7 Step 7: Identify Strategic Opportunities
2.2.8 Step 8: Final Review and Market Release
2.2.9 Step 9: Customer Feedback and Market Monitoring
U.S. DIABETIC RETINOPATHY SCREENING DEVICE MARKET
3.1 INTRODUCTION
3.2 MARKET ANALYSIS AND FORECAST
3.2.1 Aggregate Diabetic Retinopathy Screening Device Market
3.2.2 Alternative Location Diabetic Retinopathy Screening Device Market
3.2.2.1 Alternative Projection: Stable Prices and No Reimbursement
3.2.2.2 Alternative Projection: Price Erosion
3.2.2.3 Alternative Projection: Reimbursement
3.2.3 Comparison of Alternative Projections
3.3 DRIVERS AND LIMITERS
3.3.1 Market Drivers
3.3.2 Market Limiters
3.4 COMPETITIVE ANALYSIS
3.4.1 Leading Competitors
PHYSICIAN AND ADMINISTRATOR SURVEY
4.1 INTRODUCTION
4.2 AWARENESS OF ISSUE
4.3 MOTIVATION TO OBTAIN
4.3.1 Introduction
4.3.2 Results
4.3.2.1 Perceived Impact of Diabetic Retinopathy Screening Equipment
4.3.2.2 Motivation to Obtain Diabetic Retinopathy Screening Equipment
4.4 PRICE SENSITIVITY
4.5 RELATIONSHIPS WITH EYE SPECIALISTS
ABBREVIATIONS AND SURVEY APPENDIX DATA
5.1 ABBREVIATIONS
5.2 PRICING SENSITIVITY BY GROUP
5.2.1 Hospital Administrators
5.2.2 Group Practice PCPs
5.2.3 Endocrinologists
1.1 SCOPE OF STUDY
1.2 MARKET ANALYSIS AND FORECASTS
1.3 PHYSICIAN AND HOSPITAL ADMINISTRATOR SURVEY
RESEARCH METHODOLOGY
2.1 RESEARCH SCOPE
2.2 IDATA’S 9- Step METHODOLOGY
2.2.1 Step 1: Project Initiation & Team Selection
2.2.2 Step 2: Prepare Data Systems and Perform Secondary Research
2.2.3 Step 3: Preparation for Interviews & Questionnaire Design
2.2.4 Step 4: Performing Primary Research
2.2.5 Step 5: Research Analysis: Establishing Baseline Estimates
2.2.6 Step 6: Market Forecast and Analysis
2.2.7 Step 7: Identify Strategic Opportunities
2.2.8 Step 8: Final Review and Market Release
2.2.9 Step 9: Customer Feedback and Market Monitoring
U.S. DIABETIC RETINOPATHY SCREENING DEVICE MARKET
3.1 INTRODUCTION
3.2 MARKET ANALYSIS AND FORECAST
3.2.1 Aggregate Diabetic Retinopathy Screening Device Market
3.2.2 Alternative Location Diabetic Retinopathy Screening Device Market
3.2.2.1 Alternative Projection: Stable Prices and No Reimbursement
3.2.2.2 Alternative Projection: Price Erosion
3.2.2.3 Alternative Projection: Reimbursement
3.2.3 Comparison of Alternative Projections
3.3 DRIVERS AND LIMITERS
3.3.1 Market Drivers
3.3.2 Market Limiters
3.4 COMPETITIVE ANALYSIS
3.4.1 Leading Competitors
PHYSICIAN AND ADMINISTRATOR SURVEY
4.1 INTRODUCTION
4.2 AWARENESS OF ISSUE
4.3 MOTIVATION TO OBTAIN
4.3.1 Introduction
4.3.2 Results
4.3.2.1 Perceived Impact of Diabetic Retinopathy Screening Equipment
4.3.2.2 Motivation to Obtain Diabetic Retinopathy Screening Equipment
4.4 PRICE SENSITIVITY
4.5 RELATIONSHIPS WITH EYE SPECIALISTS
ABBREVIATIONS AND SURVEY APPENDIX DATA
5.1 ABBREVIATIONS
5.2 PRICING SENSITIVITY BY GROUP
5.2.1 Hospital Administrators
5.2.2 Group Practice PCPs
5.2.3 Endocrinologists
LIST OF CHARTS
Chart 1–1: Growth Rates by Forecast Alternative, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Chart 1–2: Share of Respondents “Very Interested” in Obtaining Equipment Under Alternative Pricing Scenarios, by Group
Chart 3–1: ASP vs. Unit Sales vs. Market Value, Aggregate and Alternative Location Diabetic Retinopathy Screening Device Markets, U.S., 2013
Chart 3–2: Stable Prices and No Reimbursement Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Chart 3–3: Price Erosion Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Chart 3–4: Reimbursement Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Chart 3–5: Growth Rates for Alternative Projections, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Chart 3–6: Leading Competitors, Diabetic Retinopathy Screening Equipment in Alternative Locations, U.S., 2013
Chart 4–1: Compliance Rates for Diabetic Retinopathy Screening, as Reported by Physicians and Administrators
Chart 4–2: Share of Physicians and Administrators That Prefer to Rely on an Eye Specialist to Screen Their Diabetic Patients
Chart 4–3: Perceived Impact of Diabetic Retinopathy Screening Equipment on Compliance and Detection, by Group
Chart 4–4: Compliance- and Detection-Associated Motivation to Obtain Equipment, by Group
Chart 4–5: Perceived Impact of Diabetic Retinopathy Screening Equipment on HEDIS Scores, by Group
Chart 4–6: HEDIS Score Associated Motivation to Obtain Equipment, by Group
Chart 4–7: Motivation to Obtain Equipment Based on Combined Impact of Compliance, Detection, HEDIS Score and Profitability, by Group
Chart 4–8: Percent of Respondents Willing to Obtain Under Alternative Pricing Scenarios
Chart 4–9: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Individual Practice PCPs
Chart 4–10: Percentage of Respondents Who Would Prefer to Lease, by Group
Chart 4–11: Percentage of Respondents Open to Incorporating Telemedicine Systems, by Group
Chart 4–12: Share of Administrators and Physicians Who Prefer to Rely on their Own Network of Eye Specialists
Chart 5–1: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Hospital Administrators
Chart 5–2: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Group Practice PCPs
Chart 5–3: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Endocrinologists
Chart 1–1: Growth Rates by Forecast Alternative, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Chart 1–2: Share of Respondents “Very Interested” in Obtaining Equipment Under Alternative Pricing Scenarios, by Group
Chart 3–1: ASP vs. Unit Sales vs. Market Value, Aggregate and Alternative Location Diabetic Retinopathy Screening Device Markets, U.S., 2013
Chart 3–2: Stable Prices and No Reimbursement Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Chart 3–3: Price Erosion Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Chart 3–4: Reimbursement Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Chart 3–5: Growth Rates for Alternative Projections, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Chart 3–6: Leading Competitors, Diabetic Retinopathy Screening Equipment in Alternative Locations, U.S., 2013
Chart 4–1: Compliance Rates for Diabetic Retinopathy Screening, as Reported by Physicians and Administrators
Chart 4–2: Share of Physicians and Administrators That Prefer to Rely on an Eye Specialist to Screen Their Diabetic Patients
Chart 4–3: Perceived Impact of Diabetic Retinopathy Screening Equipment on Compliance and Detection, by Group
Chart 4–4: Compliance- and Detection-Associated Motivation to Obtain Equipment, by Group
Chart 4–5: Perceived Impact of Diabetic Retinopathy Screening Equipment on HEDIS Scores, by Group
Chart 4–6: HEDIS Score Associated Motivation to Obtain Equipment, by Group
Chart 4–7: Motivation to Obtain Equipment Based on Combined Impact of Compliance, Detection, HEDIS Score and Profitability, by Group
Chart 4–8: Percent of Respondents Willing to Obtain Under Alternative Pricing Scenarios
Chart 4–9: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Individual Practice PCPs
Chart 4–10: Percentage of Respondents Who Would Prefer to Lease, by Group
Chart 4–11: Percentage of Respondents Open to Incorporating Telemedicine Systems, by Group
Chart 4–12: Share of Administrators and Physicians Who Prefer to Rely on their Own Network of Eye Specialists
Chart 5–1: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Hospital Administrators
Chart 5–2: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Group Practice PCPs
Chart 5–3: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Endocrinologists
LIST OF FIGURES
Figure 3 1: Aggregate Diabetic Retinopathy Screening Device Market, U.S., 2013
Figure 3 2: Alternative Location Diabetic Retinopathy Screening Device Market, U.S., 2013
Figure 3 3: Stable Prices and No Reimbursement Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Figure 3 4: Price Erosion Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Figure 3 5: Reimbursement Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Figure 3 6: Drivers and Limiters, Diabetic Retinopathy Screening Device Market, U.S., 2013
Figure 3 7: Leading Competitors, Diabetic Retinopathy Screening Equipment in Alternative Locations, U.S., 2013
Figure 4 1: Reported Rates of Compliance with Recommended Eye Examinations
Figure 4 2: Share of Physicians and Administrators That Prefer to Rely on an Eye Specialist to Screen Their Diabetic Patients
Figure 4 3: Perceived Impact of Diabetic Retinopathy Screening Equipment on Compliance and Detection, by Group
Figure 4 4: Compliance- and Detection-Associated Motivation to Obtain Equipment, by Group
Figure 4 5: Perceived Impact of Diabetic Retinopathy Screening Equipment on HEDIS Scores, by Group
Figure 4 6: HEDIS Score Associated Motivation to Obtain Equipment, by Group
Figure 4 7: Motivation to Obtain Equipment Based on Combined Impact of Compliance, Detection, HEDIS Score and Profitability, by Group
Figure 4 8: Percent of Respondents Willing to Obtain Under Alternative Pricing Scenarios
Figure 4 9: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Individual Practice PCPs
Figure 4 10: Payment Preferences by Group
Figure 4 11: Percent of Respondents that Make Use of Telemedicine Technology in their Practice or Organization, by Group
Figure 5 1: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Hospital Administrators
Figure 5 2: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Group Practice PCPs
Figure 5 3: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Endocrinologists
Figure 3 1: Aggregate Diabetic Retinopathy Screening Device Market, U.S., 2013
Figure 3 2: Alternative Location Diabetic Retinopathy Screening Device Market, U.S., 2013
Figure 3 3: Stable Prices and No Reimbursement Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Figure 3 4: Price Erosion Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Figure 3 5: Reimbursement Projection, Diabetic Retinopathy Screening Device Market, U.S., 2013 – 2020
Figure 3 6: Drivers and Limiters, Diabetic Retinopathy Screening Device Market, U.S., 2013
Figure 3 7: Leading Competitors, Diabetic Retinopathy Screening Equipment in Alternative Locations, U.S., 2013
Figure 4 1: Reported Rates of Compliance with Recommended Eye Examinations
Figure 4 2: Share of Physicians and Administrators That Prefer to Rely on an Eye Specialist to Screen Their Diabetic Patients
Figure 4 3: Perceived Impact of Diabetic Retinopathy Screening Equipment on Compliance and Detection, by Group
Figure 4 4: Compliance- and Detection-Associated Motivation to Obtain Equipment, by Group
Figure 4 5: Perceived Impact of Diabetic Retinopathy Screening Equipment on HEDIS Scores, by Group
Figure 4 6: HEDIS Score Associated Motivation to Obtain Equipment, by Group
Figure 4 7: Motivation to Obtain Equipment Based on Combined Impact of Compliance, Detection, HEDIS Score and Profitability, by Group
Figure 4 8: Percent of Respondents Willing to Obtain Under Alternative Pricing Scenarios
Figure 4 9: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Individual Practice PCPs
Figure 4 10: Payment Preferences by Group
Figure 4 11: Percent of Respondents that Make Use of Telemedicine Technology in their Practice or Organization, by Group
Figure 5 1: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Hospital Administrators
Figure 5 2: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Group Practice PCPs
Figure 5 3: Reported Interest in Purchasing Equipment Under Alternative Pricing Scenarios, Endocrinologists
